Company Insights

LAZ customer relationships

Explore interactive graphBrowse insights index
LAZ customer relationship map

Lazard Ltd (LAZ) — Client Mandates and What They Reveal About the Franchise

Thesis: Lazard operates as a global financial advisory and asset management franchise that monetizes through transaction and advisory fees for M&A, restructuring and capital markets work, plus recurring asset management fees tied to AUM; its economics depend on winning high‑value, short‑duration mandates with large enterprises, governments and institutional investors, while asset management provides steadier fee income. For investors, the firm’s client list—spanning multi‑billion strategic buyouts to continuation‑fund work—illustrates a sourcing model driven by reputation, sector expertise and advisory relationships rather than long‑term contracts. For a deeper view of Lazard’s customer network visit https://nullexposure.com/.

Overview: Lazard’s recent public disclosures and earnings transcripts list a wide swath of marquee mandates across healthcare, consumer, energy, telecom and private equity. The client roster demonstrates breadth (global footprint) and depth (big-ticket mandates), but revenue is not concentrated in single clients, which constrains counterparty concentration risk while tying topline to deal flow. Below I unpack operating signals, then catalog every client relationship referenced in the source material.

Visit https://nullexposure.com/ for a consolidated client relationship map and primary-source links.

How client activity translates into value

  • Lazard’s advisory fees are episodic and highly correlated with deal volume and size; largest revenue swings occur when a few large mandates close. Revenue mix and reported metrics show Financial Advisory and Asset Management as the dual engines.
  • Asset Management contributes recurring fees from institutions and HNW clients; Lazard reports roughly 82% of AUM is institutional, with the balance in family offices and individuals, creating a steady base of management fees to complement advisory volatility.
  • The firm’s win rate and sector positioning (healthcare, restructuring, energy, consumer) determine near‑term revenue visibility because most engagements are short‑term and negotiable.

Operating model signals and constraints

  • Short-term contracting posture: Investment advisory and advisory engagements are typically terminable on short notice and structured as stand‑alone mandates, which creates revenue flexibility but limits contracted revenue visibility.
  • Client mix skews large and institutional: The firm services corporations, governments, pension funds, insurers and private equity sponsors; this is an institutional business with complementary high‑net-worth work.
  • Global footprint: Revenue geography shows material exposure to Americas and EMEA and a smaller but present Asia Pacific franchise—Lazard is a global advisor.
  • Low client concentration: No single client accounted for more than 10% of segment net revenue across recent years, a structural mitigant to counterparty dependence.
  • Service provider role and active mandate pipeline: Lazard functions primarily as a professional services provider across M&A, restructuring and capital markets, and reports being actively engaged across numerous large deals.
  • Business segments balanced between transactional services and recurring asset management fees, creating a mixed cashflow profile.

Mid‑report note: for a practical tool investors use to map advisory relationships and see primary sources, check https://nullexposure.com/.

Client-by-client roll (each relationship cited to the reporting source)

  • Mars — Lazard advised on Kellanova’s $35.9 billion acquisition by Mars, a large strategic M&A assignment referenced in Lazard’s Q4 2025 remarks. Source: Lazard Q4 2025 earnings call transcript reported by InsiderMonkey (Mar 2026).
  • Keurig Dr Pepper (KDP) — Lazard supported Keurig Dr Pepper on a major coffee‑sector transaction and its planned separation, listed among FY2025 high‑profile mandates. Source: ts2.tech coverage of Lazard Q3 2025 commentary (Dec 2025).
  • Mallinckrodt Pharmaceuticals — Lazard is credited with a $6.7 billion combination with Endo Pharmaceuticals as a completed transaction cited on an FY2025 earnings transcript. Source: Lazard Q3 2025 earnings call transcript reported by InsiderMonkey (Mar 2026).
  • Endo Pharmaceuticals — Participant in the Mallinckrodt/Endo $6.7 billion combination noted in Lazard’s FY2025 disclosures. Source: InsiderMonkey Q3 2025 transcript (Mar 2026).
  • LivePerson (LPSN) — Listed among restructuring mandates and distressed issuer engagements Lazard referenced on its restructuring page and in FY2025 commentary. Source: ts2.tech summary of Lazard Q3 2025 (Dec 2025).
  • AbbVie (ABBV) — Lazard cited as an advisor on ImmunoGen’s $10.1 billion acquisition by AbbVie in a healthcare mandates summary; included in a FY2024 briefing. Source: CityBiz article summarizing Lazard client work (FY2024).
  • Biogen (BIIB) — Listed among closed healthcare transactions (acquisition of Reata Pharmaceuticals) in Lazard’s FY2024 highlights. Source: CityBiz summary of Lazard FY2024 client activity.
  • CVS Health (CVS) — Cited as advisor or involved party in CVS’s $10.6 billion acquisition of Oak Street Health referenced among Lazard’s healthcare mandates. Source: CityBiz FY2024 coverage.
  • Danaher (DHR) — Lazard listed in connection with Abcam’s $5.7 billion sale to Danaher in the FY2024 healthcare summary. Source: CityBiz FY2024.
  • EIR Partners Fund III — Lazard advised on closing EIR Partners Fund III as part of private equity assignments referenced in the Q4 2025 call. Source: InsiderMonkey Q4 2025 transcript (Mar 2026).
  • Gilead (GILD) — Lazard referenced for its role in Galderma’s IPO and related healthcare transactions that included Gilead in FY2024 summaries. Source: CityBiz FY2024.
  • Odyssey Investment Partners — Lazard advised Odyssey on a continuation‑fund assignment cited among private equity mandates in the Q4 2025 remarks. Source: InsiderMonkey Q4 2025 transcript (Mar 2026).
  • Altice France — Included in restructuring mandates and creditor agreements discussed in FY2025 materials. Source: ts2.tech coverage of Lazard Q3 2025 (Dec 2025).
  • Ferrero — Lazard worked on Ferrero’s acquisition of W.K. Kellogg and other consumer‑sector deals noted in FY2025 commentary. Source: ts2.tech summary of Lazard Q3 2025 (Dec 2025).
  • Altice International — Referenced alongside Altice France within restructuring engagements in FY2025 reporting. Source: ts2.tech Q3 2025 coverage (Dec 2025).
  • Saks Global — Cited among corporate restructuring assignments in FY2025. Source: InsiderMonkey Q3 2025 transcript (Mar 2026).
  • Corteva Agriscience (CTVA) — Named in relation to a planned restructuring and separation included in FY2025 commentary. Source: ts2.tech Q3 2025 write‑up (Dec 2025).
  • Norvestor — Advised on a continuation fund assignment listed among private equity engagements in FY2025. Source: InsiderMonkey Q3 2025 transcript (Mar 2026).
  • Sanofi (SNY) — Included in the FY2024 healthcare transaction list (Inhibrx acquisition). Source: CityBiz FY2024.
  • Vertex (VRTX) — Lazard credited in Vertex’s $4.9 billion acquisition of Alpine Immune Sciences in the FY2024 summary. Source: CityBiz FY2024.
  • Nexus Capital Management — Advised on closing of Nexus Capital Management Fund IV; cited in FY2025 client list. Source: InsiderMonkey Q3 2025 transcript (Mar 2026).
  • Anthology — Listed among corporate restructuring clients in FY2025. Source: InsiderMonkey Q3 2025 transcript (Mar 2026).
  • ODP Corporation (ODP) — Lazard noted in a transaction involving Atlas Holdings’ $1 billion acquisition of ODP in Q4 2025 commentary. Source: InsiderMonkey Q4 2025 transcript (Mar 2026).
  • ImmunoGen (IMGN) — Lazard cited for its role in ImmunoGen’s sale to AbbVie in FY2024 summaries. Source: CityBiz FY2024.
  • Oak Street Health (OSH) — Included in the CVS acquisition example that Lazard listed among healthcare transactions. Source: CityBiz FY2024.
  • Caithness Energy — Referenced for multiple transactions including a $3.8 billion asset sale to Talen Energy in FY2025 materials. Source: InsiderMonkey Q3 2025 transcript (Mar 2026).
  • JDE Peet’s (JDEP) — Part of the Keurig Dr Pepper-related strategic activity and separation discussed in FY2025. Source: InsiderMonkey Q3 2025 transcript (Mar 2026).
  • Tennant Holdings — Lazard advised on capital structure and capital raises, noted among private equity assignments in FY2025. Source: InsiderMonkey Q3 2025 transcript (Mar 2026).
  • W.K. Kellogg — Ferrero’s acquisition of W.K. Kellogg was included among completed transactions Lazard cited for FY2025. Source: InsiderMonkey Q3 2025 transcript (Mar 2026).
  • AgsoNovel — Listed in Q4 2025 as part of a $25 billion combination with Axcelta. Source: InsiderMonkey Q4 2025 transcript (Mar 2026).
  • Atlas Holdings — Referenced for its $1 billion acquisition of ODP, cited in Q4 2025 remarks. Source: InsiderMonkey Q4 2025 transcript (Mar 2026).
  • Axcelta — Named in connection with the AgsoNovel combination included in Lazard’s Q4 2025 reporting. Source: InsiderMonkey Q4 2025 transcript (Mar 2026).
  • Calpine — Cited as the target in Constellation Energy’s $26.6 billion acquisition in Lazard’s Q4 2025 listing. Source: InsiderMonkey Q4 2025 transcript (Mar 2026).
  • Cognizant (CTSH) — Lazard referenced Three Clouds’ acquisition by Cognizant in Q4 2025 transaction listings. Source: InsiderMonkey Q4 2025 transcript (Mar 2026).
  • First Brands Group — Included among debtor roles in liability management and restructuring cited in Q4 2025. Source: InsiderMonkey Q4 2025 transcript (Mar 2026).
  • Invest Industrial — Mentioned for a $2.9 billion acquisition of TreeHouse Foods referenced in Q4 2025 remarks. Source: InsiderMonkey Q4 2025 transcript (Mar 2026).
  • Kellanova — Target of the $35.9 billion acquisition by Mars listed in Lazard’s Q4 2025 completed transaction set. Source: InsiderMonkey Q4 2025 transcript (Mar 2026).
  • MotiveCare — Named in creditor roles within liability management and restructuring in Q4 2025. Source: InsiderMonkey Q4 2025 transcript (Mar 2026).
  • Next Wind — Included in capital‑structure and debt‑raising assignments in Q4 2025 materials. Source: InsiderMonkey Q4 2025 transcript (Mar 2026).
  • Pine Gate Renewables — Listed among debtor roles in liability management cited in Q4 2025. Source: InsiderMonkey Q4 2025 transcript (Mar 2026).
  • SACS Global — Identified in creditor roles for liability management and restructuring in Q4 2025. Source: InsiderMonkey Q4 2025 transcript (Mar 2026).
  • SI Group — Cited in creditor‑side restructuring engagement listings in Q4 2025. Source: InsiderMonkey Q4 2025 transcript (Mar 2026).
  • Three Clouds — Acquisition by Cognizant referenced among Q4 2025 completed transactions. Source: InsiderMonkey Q4 2025 transcript (Mar 2026).
  • Morrisons — Advised on capital structure and capital raises, noted in FY2025 private equity and advisory assignments. Source: InsiderMonkey Q3 2025 transcript (Mar 2026).
  • Pacific Avenues Fund II — Cited among private equity fund closings Lazard advised in FY2025. Source: InsiderMonkey Q3 2025 transcript (Mar 2026).
  • CVC Capital Partners — Lazard advised CVC on multiple engagements referenced in Q4 2025 materials. Source: InsiderMonkey Q4 2025 transcript (Mar 2026).
  • TreeHouse Foods (THS) — Invest Industrial’s $2.9 billion acquisition of TreeHouse Foods was listed among recent transactions in Q4 2025. Source: InsiderMonkey Q4 2025 transcript (Mar 2026).
  • Alpine Immune Sciences (ALPN) — Vertex’s $4.9 billion acquisition of Alpine Immune Sciences is listed among FY2024 healthcare mandates. Source: CityBiz FY2024.
  • Reata Pharmaceuticals (RETA) — Included in Lazard’s FY2024 healthcare transaction list (acquisition by Biogen). Source: CityBiz FY2024.
  • Boston Celtics — Lazard referenced Sixth Street’s consortium investment to acquire a controlling interest in the Boston Celtics in FY2025 materials. Source: InsiderMonkey Q3 2025 transcript (Mar 2026).
  • Galderma — Noted for an IPO in Lazard’s FY2024 healthcare highlights. Source: CityBiz FY2024.
  • CymaBay Therapeutic (CBAY) — Listed among healthcare transactions in FY2024 summaries. Source: CityBiz FY2024.
  • Constellation Energy (CEG) — Cited for the $26.6 billion acquisition of Calpine in Q4 2025 material. Source: InsiderMonkey Q4 2025 transcript (Mar 2026).
  • Ørsted (DNNGY) — Included in capital raising and capital structure mandates in Q4 2025. Source: InsiderMonkey Q4 2025 transcript (Mar 2026).
  • Talen Energy (TLN) — Named in connection to Caithness Energy asset sales in FY2025 disclosures. Source: InsiderMonkey Q3 2025 transcript (Mar 2026).
  • Lighthouse (LGHT) — Included in capital structure and debt‑raising assignment listings in Q4 2025 remarks. Source: InsiderMonkey Q4 2025 transcript (Mar 2026).
  • Inhibrx (INBX) — Sanofi’s $2.4 billion acquisition of Inhibrx is called out in Lazard’s FY2024 healthcare examples. Source: CityBiz FY2024.
  • Superior Industries (SSUP) — Listed among debtor roles for liability management in Q4 2025. Source: InsiderMonkey Q4 2025 transcript (Mar 2026).
  • Abcam (ABC) — Included in the Abcam sale to Danaher in FY2024 healthcare transactions. Source: CityBiz FY2024.
  • Sixth Street (TSLX) — Cited for its investment alongside a consortium involving the Boston Celtics acquisition referenced in FY2025. Source: InsiderMonkey Q3 2025 transcript (Mar 2026).
  • CityFibre (CFHLF) — Named among corporate restructuring assignments in FY2025. Source: InsiderMonkey Q3 2025 transcript (Mar 2026).

Conclusions for investors

  • Lazard’s revenue engine is deal‑driven and global: the breadth of clients across sectors and geographies supports fee diversification but leaves the firm exposed to M&A and restructuring cycles.
  • Low client concentration and a large institutional AUM mix reduce single‑counterparty risk, while short‑term mandates make revenue timing and visibility episodic.
  • Watch deal flow and closed high‑value mandates as the primary near‑term revenue catalysts; asset management performance will govern the steadiness of fee income.

For a structured, source‑linked visualization of Lazard’s customer ties and the primary documents cited here, visit https://nullexposure.com/. If you want a downloadable relationship map or a custom briefing that isolates counterparty risk and deal concentration for LAZ, start at https://nullexposure.com/ and request a tailored report.